胰岛素/胰高血糖素样肽-1受体激动剂联合疗法治疗2型糖尿病：两种药物是否优于一种？
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
作者信息
Aroda Vanita R, Arulandu Joseph R, Cannon Anthony J
机构信息
MedStar Health Research Institute, Hyattsville, MD.
Indiana University Health, La Porte, IN.
出版信息
Clin Diabetes. 2018 Apr;36(2):138-147. doi: 10.2337/cd17-0065.
Abstract
Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety of reasons, treatment is often not intensified in a timely manner. The combined use of basal insulin and a glucagon-like peptide-1 receptor agonist is recognized to provide a complementary approach to the treatment of type 2 diabetes. This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone. We consider the benefits and limitations of these medications based on data from randomized clinical trials and discuss how they may address barriers to treatment intensification.
摘要
鉴于2型糖尿病的进展性，通常需要强化治疗以维持血糖控制。然而，由于各种原因，治疗往往未能及时强化。基础胰岛素与胰高血糖素样肽-1受体激动剂联合使用被认为是治疗2型糖尿病的一种补充方法。本综述评估了两种复方制剂——德谷胰岛素/利拉鲁肽和甘精胰岛素/利司那肽——用于治疗仅使用单一成分药物血糖控制不佳的2型糖尿病的疗效和安全性。我们根据随机临床试验的数据考虑了这些药物的益处和局限性，并讨论了它们如何克服治疗强化的障碍。
相似文献
1
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?胰岛素/胰高血糖素样肽-1受体激动剂联合疗法治疗2型糖尿病：两种药物是否优于一种？
Clin Diabetes. 2018 Apr;36(2):138-147. doi: 10.2337/cd17-0065.
2
How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs.糖尿病如何影响日常生活？从糖化血红蛋白（A1C）之外的角度看未满足的需求。
Clin Diabetes. 2018 Apr;36(2):133-137. doi: 10.2337/cd17-0093.
3
Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.德谷胰岛素/利拉鲁肽（IDegLira）和甘精胰岛素U100/利司那肽（iGlarLixi）两种新型基础胰岛素与胰高血糖素样肽-1受体激动剂复方制剂，用于口服抗糖尿病药物治疗控制不佳的糖尿病患者的安全性和有效性。
Clin Diabetes. 2018 Apr;36(2):149-159. doi: 10.2337/cd17-0064.
4
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.直接比较两种固定比例的胰高血糖素样肽受体激动剂和基础胰岛素在 2 型糖尿病患者的血糖和非血糖参数方面的差异。
BMC Endocr Disord. 2023 Feb 1;23(1):28. doi: 10.1186/s12902-023-01282-w.
5
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.在 2 型糖尿病患者中，具有基础胰岛素类似物和胰高血糖素样肽 1 受体激动剂的可滴定固定比例复方制剂的理由。
Curr Med Res Opin. 2019 May;35(5):793-804. doi: 10.1080/03007995.2018.1541790. Epub 2018 Nov 27.
6
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.德谷胰岛素/利拉鲁肽（IDegLira）用于治疗2型糖尿病。
Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. doi: 10.1586/17446651.2016.1113129. Epub 2015 Nov 18.
7
Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles?胰岛素与胰高血糖素样肽-1受体激动剂联合使用：简化治疗还是增加障碍？
J Pharm Pract. 2019 Aug;32(4):447-449. doi: 10.1177/0897190017753041. Epub 2018 Oct 1.
8
Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.精蛋白锌重组赖脯胰岛素混合注射液（25R）基础上固定比例联用利西拉来肽：简化 2 型糖尿病患者血糖控制方案。
Diabetes Res Clin Pract. 2020 Dec;170:108478. doi: 10.1016/j.diabres.2020.108478. Epub 2020 Sep 28.
9
Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.以肠促胰岛素为基础的疗法和钠-葡萄糖协同转运蛋白2抑制剂作为胰岛素治疗辅助手段在2型糖尿病中的作用，特别提及德谷胰岛素利拉鲁肽。
Diabet Med. 2016 Jul;33(7):864-76. doi: 10.1111/dme.13021. Epub 2015 Dec 8.
10
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.关于 2 型糖尿病中胰岛素-GLP-1 受体激动剂联合用药安全性的最新信息。
Expert Opin Drug Saf. 2022 Mar;21(3):349-361. doi: 10.1080/14740338.2021.1978974. Epub 2021 Oct 13.
引用本文的文献
1
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2022 年美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的共识报告：2 型糖尿病患者高血糖管理。
Diabetologia. 2022 Dec;65(12):1925-1966. doi: 10.1007/s00125-022-05787-2. Epub 2022 Sep 24.
2
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2022 年美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 共识报告：2 型糖尿病患者高血糖管理。
Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.
3
Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.利拉鲁肽通过下调晚期糖基化终产物受体改善糖尿病小鼠的认知功能。
Aging (Albany NY). 2020 Nov 26;13(1):525-536. doi: 10.18632/aging.202162.
4
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.基于达到临床相关治疗目标评估德谷胰岛素利拉鲁肽与基础胰岛素和基础-餐时胰岛素强化方案治疗 2 型糖尿病的短期成本-效果。
J Manag Care Spec Pharm. 2020 Feb;26(2):143-153. doi: 10.18553/jmcp.2019.19035. Epub 2019 Dec 19.
5
Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.在一项 3 期、双盲、随机临床试验中，与最大剂量 50 单位的德谷胰岛素相比，固定比例的德谷胰岛素和利拉鲁肽（IDegLira）组合可实现更好的 HbA1c 控制，用于日本 2 型糖尿病患者。
Diabetes Obes Metab. 2019 Dec;21(12):2694-2703. doi: 10.1111/dom.13859. Epub 2019 Sep 17.
6
Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.利西拉来/甘精胰岛素固定比例复方治疗 2 型糖尿病患者的血糖达标情况：LixiLan-O 和 LixiLan-L 试验的事后分析。
Diabet Med. 2020 Feb;37(2):256-266. doi: 10.1111/dme.14094. Epub 2019 Nov 26.
7
There Are Great New Medications Out There-Why Aren't We Using Them?有很多很棒的新药——我们为什么不用它们呢？
Clin Diabetes. 2018 Apr;36(2):97-98. doi: 10.2337/cd18-0011.
本文引用的文献
1
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.德谷胰岛素与甘精胰岛素U100对2型糖尿病患者低血糖影响的研究：SWITCH 2随机临床试验
JAMA. 2017 Jul 4;318(1):45-56. doi: 10.1001/jama.2017.7117.
2
Comment on American Diabetes Association. . Diabetes Care 2017;40(Suppl. 1):S1-S135.对美国糖尿病协会的评论。《糖尿病护理》2017年；40（增刊1）：S1 - S135。
Diabetes Care. 2017 Jul;40(7):e92-e93. doi: 10.2337/dc17-0299.
3
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.德谷胰岛素与甘精胰岛素治疗2型糖尿病的疗效和安全性比较
N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.
4
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法（2017年执行摘要）的共识声明。
Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.
5
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.德谷胰岛素利拉鲁肽（胰岛素德谷/利拉鲁肽组合）用于经GLP-1受体激动剂和口服治疗血糖控制不佳的2型糖尿病成人患者的疗效：DUAL III随机临床试验
Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10.
6
Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization.美国社区环境中初用基础胰岛素的2型糖尿病患者的低血糖：对治疗中断和住院的影响
Curr Med Res Opin. 2017 Feb;33(2):209-214. doi: 10.1080/03007995.2016.1248911. Epub 2016 Nov 4.
7
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013.2006 - 2013年药物使用、血糖控制及严重低血糖发生率的趋势
Diabetes Care. 2017 Apr;40(4):468-475. doi: 10.2337/dc16-0985. Epub 2016 Sep 22.
8
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.利西拉来，一种基础胰岛素联合二甲双胍血糖控制不佳的 2 型糖尿病患者的可滴定固定比例复方制剂：LixiLan-L 随机试验的疗效和安全性。
Diabetes Care. 2016 Nov;39(11):1972-1980. doi: 10.2337/dc16-1495. Epub 2016 Sep 20.
9
Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets.基础胰岛素治疗的患者血糖达标情况如何？接受基础胰岛素治疗的 2 型糖尿病患者的特征及血糖达标情况和医生认为的血糖达标障碍。
Diabetes Res Clin Pract. 2016 Nov;121:17-26. doi: 10.1016/j.diabres.2016.08.004. Epub 2016 Aug 24.
10
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.利拉鲁肽每日 1 次与利西那肽作为二甲双胍的附加疗法用于 2 型糖尿病：一项 26 周随机对照临床试验。
Diabetes Care. 2016 Sep;39(9):1501-9. doi: 10.2337/dc15-2479. Epub 2016 Jun 16.
Zotero 插件